Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA)
| Autor: | Chengliang Yang, Aihua Shu, Mi Zhou, Chen Xiaobo, Chenhong Huang, Leyun Zhan, Yulin Zhang, Yaojun Tan, Qiongya Wu, Bingyi Zhang |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Gene isoform endocrine system promoter methylation 03 medical and health sciences Sex Factors 0302 clinical medicine Biomarkers Tumor medicine Quantitative assessment Humans Promoter Regions Genetic Domain family Survival analysis Neoplasm Staging Proportional Hazards Models Genetics Bladder cancer business.industry Tumor Suppressor Proteins Age Factors Promoter RASSF1A General Medicine Methylation DNA Methylation TCGA medicine.disease Survival Analysis meta-analysis 030104 developmental biology Urinary Bladder Neoplasms 030220 oncology & carcinogenesis DNA methylation ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Cancer research business Systematic Review and Meta-Analysis Research Article |
| Zdroj: | Medicine |
| ISSN: | 0025-7974 |
| DOI: | 10.1097/md.0000000000006097 |
| Popis: | Supplemental Digital Content is available in the text Background: Methylation of the Ras-association domain family 1 isoform A (RASSF1A) gene promoter region is thought to participate in the initiation and development of many different cancers. However, in bladder cancer the role of RASSF1A methylation was unclear. To evaluate the relationship between RASSF1A methylation and bladder cancer, a quantitative assessment of an independent meta-analysis was performed. In addition, a DNA methylation microarray database from the cancer genome atlas (TCGA) project was used to validate the results of the meta-analysis. Methods: We searched published articles from computerized databases, and DNA methylation data were extracted from TCGA project. All data were analyzed by R software. Results: The results of the meta-analysis indicated that the frequency of RASSF1A gene methylation in bladder cancer patients is significantly higher than in healthy controls. The hazard ratio (HR) was 2.24 (95% CI = [1.45; 3.48], P = 0.0003) for overall survival (OS), and the RASSF1A gene promoter methylation status was strongly associated with the TNM stage and differentiation grade of the tumor. The similar results were also found by the data from TCGA project. Conclusion: There was a significant relationship between the methylation of the RASSF1A gene promoter and bladder cancer. Therefore, RASSF1A gene promoter methylation will be a potential biomarker for the clinical diagnosis of bladder cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|